Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
Purpose
The study is a Phase II clinical trial. Patients will receive intensity modulated total body irradiation (TBI) at a dose of 3 Gy with standard fludarabine/ i.v. cyclophosphamide conditioning prior to human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell transplant (HSCT). The primary objective of the study is to determine the engraftment at Day +60 following HLA-haploidentical hematopoietic stem cell transplant protocol using immunosuppressive agents and low-dose total body irradiation (TBI) for conditioning and post-transplant cyclophosphamide in patients with sickle cell disease.
Condition
- Sickle Cell Disease
Eligibility
- Eligible Ages
- Between 16 Years and 60 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Criteria
Patient Eligibility:
1. Patients with sickle cell disease are eligible if they have any of the following
complications:
1.1 Stroke or central nervous system event lasting longer than 24 hours 1.2 Frequent
vaso-occlusive pain episodes, defined as ≥ 3 per year requiring emergency room,
acute care center, hospital admissions, or home bedrest leading to absence from work
or school. 1.3 Recurrent episodes of priapism, defined as ≥ 2 per year requiring
emergency room visits 1.4 Acute chest syndrome with recurrent hospitalizations,
defined as ≥ 2 lifetime events 1.5 Red-cell alloimmunization (≥ 2 antibodies) during
long-term transfusion therapy 1.6 Bilateral proliferative retinopathy with major
visual impairment in at least one eye 1.7 Osteonecrosis of 2 or more joints 1.8
Sickle cell nephropathy, defined by a GFR < 90mL/min/1.73m2 or the presence of
macroalbuminuria (urine albumin > 300 mg/g creatinine) 1.9 Pulmonary hypertension,
defined by a mean pulmonary arterypressure >25mmHg
2. Age 16-60 years
3. Karnofsky performance status of 60 or higher (Appendix A)
4. Adequate cardiac function, defined as left ventricular ejection fraction ≥ 40%
5. Adequate pulmonary function, defined as diffusion lung capacity of carbon monoxide ≥
50% predicted (after adjustment for hemoglobin concentration)
6. Estimated GFR ≥ 50mL/min/1.73m2 as calculated by the modified MDRD equation
7. ALT ≤ 3x upper limit of normal
8. HIV-negative
9. Patient is not pregnant
10. Patient is able and willing to sign informed consent
11. Patient does not have a fully HLA-matched sibling donor
12. Patient has an HLA-haploidentical relative
Donor Eligibility Relatives (parents, offspring, siblings, aunts/uncles, cousins) will be
tested by molecular typing of HLA class I (A, B, and C) and class II (DRB1) at low
resolution. Only those that are an HLA-haploidentical match (≥ 4/8) will be considered as
a potential donor. NOTE: If during testing, a fully HLA-matched sibling donor is found
and is willing to donate his/her stem cells, the potential subject will not be eligible
for this protocol.
Donor consent will be obtained as per standard protocol of the bone marrow transplant
unit.
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Subject treatment |
Patients will receive the following conditioning regimen: ATG, fludarabine (6 days before stem cell infusion), cyclophosphamide, and total body irradiation. The stem cell product will be infused according to BMT unit policy. Patients will also receive GVHD prophylaxis which will consist of cyclophosphamide, sirolimus, and mycophenolate mofetil according to the protocol. Post-transplant evaluation will be done as per standard care with study data collected at days 30, 60, 100, 180, 365, and annually thereafter. |
|
Recruiting Locations
Chicago, Illinois 60612
More Details
- Status
- Recruiting
- Sponsor
- University of Illinois at Chicago